Drug intelligence / Profile preview

cenicriviroc

Development stage: Phase 3
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

Cenicriviroc is an orally bioavailable, small molecule dual antagonist of the human C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5). By binding to and inhibiting these receptors, cenicriviroc blocks their activation and downstream signaling pathways. This action results in immunomodulatory, anti-inflammatory, antifibrotic, and antiviral effects. The drug has been investigated for the treatment of HIV infection—where it acts as a viral entry inhibitor by blocking CCR5—and for nonalcoholic steatohepatitis (NASH) with liver fibrosis due to its ability to inhibit inflammatory cell migration and reduce fibrogenesis. Cenicriviroc is being developed by Takeda and Tobira Therapeutics[1][3][4][5].

Other names: cenicriviroc mesylate

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on cenicriviroc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cenicriviroc.

Explore the full profile